Skip to content

ARC synaptic adaptation therapy: A new treatment for tinnitus

ARC synaptic stabilization: Synaptic adaptation therapy as a new treatment for tinnitus trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18341063
Enrollment
38
Registered
2017-03-30
Start date
2016-04-24
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus Ear, Nose and Throat Tinnitus

Interventions

Participants are randomly allocated to either the control group or the intervention group (this is done using a coin toss). Participants are given a synaptic adapter (tone generator) with a stimulatio

Sponsors

Bioacoustic LTD
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both women and men 2. Age between 18 and 60 years of age 3. Must be right-handed 4. Must suffer from permanent tinnitus 5. Tinnitus must not last longer than for 2 years 6. Only two persons with tinnitus lasting for more than 2 years may participate in the trial 7. Tinnitus may be tone or wide-band one 8. Tinnitus heard in head or ear 9. Movement or sight may modulate tinnitus 11. Have a high level of serotonin tested in the laboratory in serum or blood plasma (>100 µg/l ) 12. Small difference in the HDL- LDL cholesterol units of the patient; it should be at the level of 1:1 or very similar (high level of BDNF protein) 14. Hearing loss in the range between 10 kHz and 20 kHz 15. Tinnitus occurs due to the model of increased synapse activity (Tinnitus does not require macroscopic tonotopic map reorganization) 16. Follows the recommendation referring to the diet and physical activity which notified to it before the clinical trial 17. Auditory canals must not be obstructed during the therapy, no inflammation of the middle ear before commencing of the treatment and during its course 18. Average loss of hearing of the patient noted on audiogram does not exceed the level of 70 dB for a single frequency 19. Apart from the gradual loss of hearing the patient had to experience also the sudden loss of hearing visible in the background of dead outer hair cells in the range from 10 to 20 kHz 20. Does not work in the noise 21. Does not suffer from depression, anxieties, sleep disorders

Exclusion criteria

Exclusion criteria: 1. Suffers from hearing loss that starts already in the range of from 125 Hz to 10 kHz in one or both ears 2. Suffers from a chronic disease, such as diabetes, kidney failure, cancer 3. Tinnitus is pulsed or not continued 4. Model of nervous system plasticity, increased synchronization, which assumes that the nervous system of the patient underwent the neurons migration process or the reorganization of the auditory cortex, which additionally leads to auditory oversensitivity 5. Auditory Hyperacusis (a negative symptom of hidden hearing loss in the scope of proper hearing or increased synchronization model) 6. The hearing loss exceeds 70 dB of the single frequency 7. In audiogram, the patient manifests a dead zone of the inner ear (destroyed external and internal hair cells) 8. Partially or deaf in one or both ears 9. The auditory canal of the patient obstructed due to cerumen or inflammation of the middle ear 10. Serotonin level of the patient is lower than required. 11. Manifests metabolic disorders, which cannot be adjusted with diet and physical activity (hyperlipidemia), congenital heart disease, in spite of following the diet and physical activities there is a big difference between HDL and LDL cholesterol and high level of triglycerides 12. Works in noise 13. Suffers from depression, anxieties, sleep disorders 14. Does not want to follow the diet and physical activities

Design outcomes

Primary

MeasureTime frame
Tinnitus reduction is measured by using a tinnitus patient questionnaire at baseline and 4 months

Secondary

MeasureTime frame
There are no secondary outcome measures

Countries

Poland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026